Nanoparticles News and Research

RSS

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Spanish Medicines Agency grants IMP License to Midatech's clinical grade nanoparticles

Midatech Biogune S. L., the nanoparticle manufacturing subsidiary of the Midatech Group, a global leader and centre of excellence for the design, development, synthesis and manufacture of nanomedicines, is pleased to announce that it has been granted an Investigational Medicinal Products (IMP) License from the Spanish Medicines Agency for the cGMP manufacture of clinical grade nanoparticles at its state-of-the art facility in Bilbao, Spain.

1 Jun 2011

Quantum sensors could aid in development of new drugs and nanomedicine

Groundbreaking research has shown a quantum atom has been tracked inside a living human cell and may lead to improvements in the testing and development of new drugs.

26 May 2011

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

The American Academy of Dermatology today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer.

24 May 2011

CHOP forms first startup firm to develop treatments for peripheral artery disease

Building on its extensive laboratory research using magnetically guided nanoparticles to deliver drugs to diseased blood vessels, The Children's Hospital of Philadelphia has just spun off its first startup company, Vascular Magnetics, Inc.

10 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

New MIT drug-delivery nanoparticle could target any type of tumor

MIT chemical engineers have designed a new type of drug-delivery nanoparticle that exploits a trait shared by almost all tumors: They are more acidic than healthy tissues.

4 May 2011

Portuguese researcher to earn Bill & Melinda Gates Foundation award for new HIV therapy

João Gonçalves, from Faculdade de Farmácia e Instituto de Medicina Molecular, Lisbon, Portugal, to win a Grand Challenges Exploration Award

29 Apr 2011

New nanoparticle imaging agent can help diagnose heart disease, breast cancer

Scientists are reporting development of a process for producing large quantities of a much-needed new imaging agent for computed tomography scans in heart disease, breast cancer and other diseases, and the first evidence that the material is safe for clinical use.

28 Apr 2011

Magnetic 'nanobeads' help detect chemical and biological agents

Researchers at Oregon State University have found a way to use magnetic "nanobeads" to help detect chemical and biological agents, with possible applications in everything from bioterrorism to medical diagnostics, environmental monitoring or even water and food safety.

27 Apr 2011

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

There's no question, drugs work in treating disease. But can they work better, and safer?

22 Apr 2011

Research solves challenging problem of industry-scale production of large RNA molecules

Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.

22 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

Medicinal applications of fullerenes, filled with radioactive material

Fullerenes have attracted considerable attention in different fields of science since their discovery in 1985. Investigations of physical, chemical and biological properties of fullerenes have yielded promising information. It is inferred that size, hydrophobicity, three-dimensionality and electronic configurations make them an appealing subject in medicinal chemistry. Their unique carbon cage structure coupled with immense scope for derivatization make them a potential therapeutic agent.

13 Apr 2011

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.

8 Apr 2011

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.

7 Apr 2011

Study explores physical effect of freeway pollution on brain cells

If mice commuted, their brains might find it progressively harder to navigate the maze of Los Angeles freeways.

7 Apr 2011

Morphotek acquires tumor targeting assets from TMI

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. for an undisclosed upfront payment and future development milestones.

4 Apr 2011

Study: Nanoparticles can prevent nickel-induced dermatitis

Tiny particles only billionths of a meter in diameter-about two thousand would fit across the width of a human hair-could offer big hope in a small package to the many millions of people who are allergic to the nickel in everything from jewelry to coins and cell phones, say scientists at Brigham and Women's Hospital.

4 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011